person · Reporting owner

BIENAIME JEAN JACQUES

Disclosed activity across 6 companies

Tapewire entity: 21586
SEC CIK: 0001221590

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Ascendis Pharma A/SASND · Entity 1628	Director	April 14, 2026	September 28, 2026
IMMUNIC, INC.VTL · Entity 6306	Director	September 24, 2018	September 24, 2018
INCYTE CORPINCY · Entity 3182	Director	June 08, 2026	June 10, 2026
Immunome Inc.IMNM · Entity 4219	Director	June 10, 2026	June 12, 2026
Keros Therapeutics, Inc.KROS · Entity 6242	Director	August 17, 2026	August 19, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Ascendis Pharma A/S

Report date April 14, 2026 · Filed September 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $172.35 · Expires 2035-06-10	Direct	0	Reported balance After 2026-04-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-04-14 · Disposition to issuer · Disposed 9,160 · Balance 0 F2: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer. F1: The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments.
WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $249.84 · Expires 2036-04-14	Direct	9,160	Reported balance After 2026-04-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-14 · Grant · Acquired 9,160 · Balance 9,160 F2: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer. F3: The warrants vest 25% on April 14, 2027 and thereafter in 36 equal monthly installments.

Filing footnotes · ownership attribution and instrument terms

F1: The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments.

F2: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer.

F3: The warrants vest 25% on April 14, 2027 and thereafter in 36 equal monthly installments.

IMMUNIC, INC.

Report date September 24, 2018 · Filed September 24, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	18,500	Reported balance After 2018-09-24 transaction · row 1 1 source row Row 1 · 2018-09-24 · Sale · Disposed 26,619 · Balance 18,500 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.30 to $0.3021. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.30 to $0.3021. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4.

INCYTE CORP

Report date June 08, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	24,424	Reported balance After 2026-06-08 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-08 · Grant · Acquired 1,642 · Balance 24,424 F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
Non Qualfied Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.64 · Expires 2036-06-07	Direct	6,111	Reported balance After 2026-06-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-08 · Grant · Acquired 6,111 · Balance 6,111 F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

Filing footnotes · ownership attribution and instrument terms

F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

Immunome Inc.

Report date June 10, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.16 · Expires 2036-06-09	Direct	9,897	Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-10 · Grant · Acquired 9,897 · Balance 9,897 F1: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.

Keros Therapeutics, Inc.

Report date August 17, 2026 · Filed August 19, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	19,592	Reported balance After 2026-08-17 transaction · row 1 1 source row Row 1 · 2026-08-17 · Purchase · Acquired 1,000 · Balance 19,592 F1: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.02 to $10.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.

F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.02 to $10.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

BIOMARIN PHARMACEUTICAL INC

Report date May 20, 2024 · Filed May 21, 2024

Section 16 reporting ended · disclosed 2024-05-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	473,792	Reported balance After 2024-05-20 transaction · row 1 1 source row Row 1 · 2024-05-20 · Tax withholding · Disposed 1,202 · Balance 473,792
Common StockSEC Table I · non-derivative	IndirectShares held by Jean-Jacques Bienaime Family Trust	247,333	Reported balance Holding disclosure · report date 2024-05-20 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 247,333
Common StockSEC Table I · non-derivative	IndirectShares held as UTMA custodian for child 1	100	Reported balance Holding disclosure · report date 2024-05-20 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 100
Common StockSEC Table I · non-derivative	IndirectShares held as UTMA custodian for child 2	100	Reported balance Holding disclosure · report date 2024-05-20 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 100

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 17, 2026 Filed Aug 19, 2026 20:10 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	PurchaseCommon Stock	1,000	$10.27	$10,270.00	Disclosure SEC source: 0001221590-26-000025 · form4-08192026_040802.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,592 F1 · kind: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.02 to $10.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
August 14, 2026 Filed Aug 19, 2026 01:02 UTC	Ascendis Pharma A/S ASND · Entity 1628	PurchaseOrdinary Shares	900	$246.91	$222,219.00	Disclosure SEC source: 0001610717-26-000360 · form4.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,900 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $246.48 to $247.32 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
August 14, 2026 Filed Aug 19, 2026 01:02 UTC	Ascendis Pharma A/S ASND · Entity 1628	PurchaseOrdinary Shares	1,100	$245.85	$270,435.00	Disclosure SEC source: 0001610717-26-000360 · form4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $245.41 to $246.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
July 15, 2026 Filed Jul 17, 2026 20:10 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	PurchaseCommon Stock	1,000	$10.61	$10,610.00	Disclosure SEC source: 0001221590-26-000023 · form4-07172026_040701.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,592 F1 · kind: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.46 to $10.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
June 15, 2026 Filed Jun 17, 2026 20:55 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	PurchaseCommon Stock	1,000	$10.19	$10,190.00	Disclosure SEC source: 0001221590-26-000021 · form4-06172026_080646.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,592 F1 · kind: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.99 to $10.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
June 10, 2026 Filed Jun 12, 2026 21:54 UTC	Immunome Inc. IMNM · Entity 4219	GrantDirector Stock Option (right to buy) · Derivative	9,897	$0.00 Strike: $18.16	$0.00	Disclosure SEC source: 0001221590-26-000018 · form4-06122026_090608.xml · derivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,897 Underlying: Common Stock · 9,897 shares Expires 2036-06-09 F1 · derivative.exercise_date: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date. Read SEC document
June 08, 2026 Filed Jun 10, 2026 20:06 UTC	INCYTE CORP INCY · Entity 3182	GrantNon Qualfied Stock Option (right to buy) · Derivative	6,111	$0.00 Strike: $100.64	$0.00	Disclosure SEC source: 0001221590-26-000017 · wk-form4_1781121966.xml · derivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,111 Underlying: Common Stock · 6,111 shares Expires 2036-06-07 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document
June 08, 2026 Filed Jun 10, 2026 20:06 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	1,642	$0.00	$0.00	Disclosure SEC source: 0001221590-26-000017 · wk-form4_1781121966.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,424 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
June 05, 2026 Filed Jun 9, 2026 21:40 UTC	Immunome Inc. IMNM · Entity 4219	PurchaseCommon Stock	1,000	$19.27	$19,270.00	Disclosure SEC source: 0001221590-26-000015 · form4-06092026_090607.xml · nonDerivative · entry 5 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,415 F1 · kind: The sales by the reporting person reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934 with the purchase of 1,000 shares of the Issuer's common stock by the reporting person at the price of $19.27 per share on June 5, 2026. The reporting person has agreed to pay to the Issuer upon settlement of the sale, $155, representing the full amount of the profit realized in connection with the short-swing transaction. F2 · kind: The reporting person sold and reacquired the same aggregate number of shares on June 5, 2026. Read SEC document
June 05, 2026 Filed Jun 9, 2026 21:40 UTC	Immunome Inc. IMNM · Entity 4219	PurchaseCommon Stock	3,500	$19.46	$68,110.00	Disclosure SEC source: 0001221590-26-000015 · form4-06092026_090607.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,415 F2 · kind: The reporting person sold and reacquired the same aggregate number of shares on June 5, 2026. Read SEC document
June 05, 2026 Filed Jun 9, 2026 21:40 UTC	Immunome Inc. IMNM · Entity 4219	PurchaseCommon Stock	6,000	$19.48	$116,880.00	Disclosure SEC source: 0001221590-26-000015 · form4-06092026_090607.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,915 F2 · kind: The reporting person sold and reacquired the same aggregate number of shares on June 5, 2026. Read SEC document
June 05, 2026 Filed Jun 9, 2026 21:40 UTC	Immunome Inc. IMNM · Entity 4219	SaleCommon Stock	10,000	$19.41	$194,100.00	Disclosure SEC source: 0001221590-26-000015 · form4-06092026_090607.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,915 F1 · kind: The sales by the reporting person reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934 with the purchase of 1,000 shares of the Issuer's common stock by the reporting person at the price of $19.27 per share on June 5, 2026. The reporting person has agreed to pay to the Issuer upon settlement of the sale, $155, representing the full amount of the profit realized in connection with the short-swing transaction. F2 · kind: The reporting person sold and reacquired the same aggregate number of shares on June 5, 2026. Read SEC document
June 05, 2026 Filed Jun 9, 2026 21:40 UTC	Immunome Inc. IMNM · Entity 4219	SaleCommon Stock	500	$19.44	$9,720.00	Disclosure SEC source: 0001221590-26-000015 · form4-06092026_090607.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,915 F1 · kind: The sales by the reporting person reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934 with the purchase of 1,000 shares of the Issuer's common stock by the reporting person at the price of $19.27 per share on June 5, 2026. The reporting person has agreed to pay to the Issuer upon settlement of the sale, $155, representing the full amount of the profit realized in connection with the short-swing transaction. F2 · kind: The reporting person sold and reacquired the same aggregate number of shares on June 5, 2026. Read SEC document
June 03, 2026 Filed Jun 5, 2026 20:15 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	GrantStock Option (right to buy) · Derivative	7,433	$0.00 Strike: $10.50	$0.00	Disclosure SEC source: 0001221590-26-000013 · form4-06052026_040601.xml · derivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,433 Underlying: Common Stock · 7,433 shares Expires 2036-06-02 F2 · derivative.exercise_date: The option shall vest in equal quarterly installments over the 12 months following June 3, 2026, provided that the grant will in any case be fully vested on the date of Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
June 03, 2026 Filed Jun 5, 2026 20:15 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	GrantCommon Stock	7,142	$0.00	$0.00	Disclosure SEC source: 0001221590-26-000013 · form4-06052026_040601.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,592 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
May 29, 2026 Filed Jun 1, 2026 20:11 UTC	Ascendis Pharma A/S ASND · Entity 1628	PurchaseOrdinary Shares	100	$223.50	$22,350.00	Disclosure SEC source: 0001610717-26-000177 · form4.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900 Read SEC document
May 29, 2026 Filed Jun 1, 2026 20:11 UTC	Ascendis Pharma A/S ASND · Entity 1628	PurchaseOrdinary Shares	200	$222.30	$44,460.00	Disclosure SEC source: 0001610717-26-000177 · form4.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800 Read SEC document
May 29, 2026 Filed Jun 1, 2026 20:11 UTC	Ascendis Pharma A/S ASND · Entity 1628	PurchaseOrdinary Shares	200	$223.76	$44,752.00	Disclosure SEC source: 0001610717-26-000177 · form4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600 Read SEC document
May 26, 2026 Filed May 27, 2026 20:05 UTC	Ascendis Pharma A/S ASND · Entity 1628	PurchaseOrdinary Shares	200	$239.37	$47,873.50	Disclosure SEC source: 0001610717-26-000161 · form4.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $239.245 to $239.490 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
May 26, 2026 Filed May 27, 2026 20:05 UTC	Ascendis Pharma A/S ASND · Entity 1628	PurchaseOrdinary Shares	200	$236.24	$47,247.00	Disclosure SEC source: 0001610717-26-000161 · form4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $235.93 to $236.54 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
May 26, 2026 Filed May 28, 2026 20:03 UTC	INCYTE CORP INCY · Entity 3182	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	15,000	$0.00 Strike: $84.53	$0.00	Disclosure SEC source: 0001221590-26-000011 · wk-form4_1779998588.xml · derivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document
May 26, 2026 Filed May 28, 2026 20:03 UTC	INCYTE CORP INCY · Entity 3182	Tax withholdingCommon Stock	13,059	$97.10	$1,268,028.90	Disclosure SEC source: 0001221590-26-000011 · wk-form4_1779998588.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,782 F1 · acquired: Represents shares withheld automatically by the Issuer to satisfy the payment of the cost of exercise the option award previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
May 26, 2026 Filed May 28, 2026 20:03 UTC	INCYTE CORP INCY · Entity 3182	Exercise / conversionCommon Stock	15,000	$84.53	$1,267,950.00	Disclosure SEC source: 0001221590-26-000011 · wk-form4_1779998588.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 15, 2026 Filed May 19, 2026 11:56 UTC	Immunome Inc. IMNM · Entity 4219	PurchaseCommon Stock	5,000	$20.70	$103,500.00	Disclosure SEC source: 0001221590-26-000007 · form4-05192026_110547.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,415 F1 · price: The weighted average purchase price for the transaction report was $20.70, and the range of prices were between $20.645 and $20.72, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document
May 15, 2026 Filed May 19, 2026 20:15 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	PurchaseCommon Stock	1,000	$10.58	$10,580.00	Disclosure SEC source: 0001221590-26-000009 · form4-05192026_040503.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,450 F1 · kind: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.44 to $10.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 15, 2026 Filed Apr 17, 2026 20:15 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	PurchaseCommon Stock	1,000	$11.70	$11,700.00	Disclosure SEC source: 0001221590-26-000005 · form4-04172026_040401.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,450 F1 · kind: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.56 to $11.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 14, 2026 Filed Sep 28, 2026 20:08 UTC	Ascendis Pharma A/S ASND · Entity 1628	GrantWarrants · Derivative	9,160	Not disclosed Strike: $249.84	Not disclosed	Disclosure SEC source: 0001610717-26-000423 · form4.xml · derivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,160 Underlying: Ordinary Shares · 9,160 shares Expires 2036-04-14 F2 · price: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer. F3 · derivative.exercise_date: The warrants vest 25% on April 14, 2027 and thereafter in 36 equal monthly installments. Read SEC document
April 14, 2026 Filed Sep 28, 2026 20:08 UTC	Ascendis Pharma A/S ASND · Entity 1628	Disposition to issuerWarrants · Derivative	9,160	Not disclosed Strike: $172.35	Not disclosed	Disclosure SEC source: 0001610717-26-000423 · form4.xml · derivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,160 shares Expires 2035-06-10 F2 · price: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer. F1 · derivative.exercise_date: The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments. Read SEC document
March 11, 2026 Filed Mar 12, 2026 10:05 UTC	Immunome Inc. IMNM · Entity 4219	PurchaseCommon Stock	1,000	$21.55	$21,550.00	Disclosure SEC source: 0001221590-26-000003 · form4-03122026_060301.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,415 Read SEC document
March 10, 2026 Filed Mar 12, 2026 10:05 UTC	Immunome Inc. IMNM · Entity 4219	PurchaseCommon Stock	1,000	$22.12	$22,120.00	Disclosure SEC source: 0001221590-26-000003 · form4-03122026_060301.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,415 Read SEC document
March 09, 2026 Filed Mar 11, 2026 20:33 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	PurchaseCommon Stock	2,000	$11.21	$22,420.00	Disclosure SEC source: 0001221590-26-000002 · form4-03112026_080355.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,450 F1 · kind: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.98 to $11.48 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:30 UTC	INCYTE CORP INCY · Entity 3182	GrantNon Qualfied Stock Option (right to buy) · Derivative	9,216	$0.00 Strike: $70.07	$0.00	Disclosure SEC source: 0001628280-25-031009 · wk-form4_1749760200.xml · derivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,216 Underlying: Common Stock · 9,216 shares Expires 2035-06-09 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:30 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	2,518	$0.00	$0.00	Disclosure SEC source: 0001628280-25-031009 · wk-form4_1749760200.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,841 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including this grant, this includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:52 UTC	Immunome Inc. IMNM · Entity 4219	GrantDirector Stock Option (right to buy) · Derivative	18,864	$0.00 Strike: $9.57	$0.00	Disclosure SEC source: 0001415889-25-016980 · form4-06122025_080623.xml · derivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,864 Underlying: Common Stock · 18,864 shares Expires 2035-06-09 F1 · derivative.exercise_date: The option vests in four quarterly installments, commencing from June 10, 2025 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date. Read SEC document
June 04, 2025 Filed Jun 6, 2025 20:15 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	GrantStock Option (right to buy) · Derivative	10,500	$0.00 Strike: $14.82	$0.00	Disclosure SEC source: 0001415889-25-015971 · form4-06062025_040601.xml · derivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2035-06-03 F2 · derivative.exercise_date: The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
June 04, 2025 Filed Jun 6, 2025 20:15 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	GrantCommon Stock	5,250	$0.00	$0.00	Disclosure SEC source: 0001415889-25-015971 · form4-06062025_040601.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,450 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 4, 2026 and (B) the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
June 03, 2025 Filed Jun 4, 2025 01:21 UTC	Immunome Inc. IMNM · Entity 4219	PurchaseCommon Stock	5,000	$9.38	$46,900.00	Disclosure SEC source: 0001415889-25-015478 · form4-06042025_010636.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,415 F1 · price: The weighted average purchase price for the transaction report was $9.38, and the range of prices were between $9.36 and $9.40, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document
March 25, 2025 Filed Mar 26, 2025 20:05 UTC	Immunome Inc. IMNM · Entity 4219	PurchaseCommon Stock	7,800	$7.78	$60,684.00	Disclosure SEC source: 0001415889-25-009019 · form4-03262025_080315.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,415 F1 · price: The weighted average purchase price for the transaction report was $7.78, and the range of prices were between $7.37 and $8.51, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document
March 24, 2025 Filed Mar 25, 2025 21:18 UTC	Immunome Inc. IMNM · Entity 4219	PurchaseCommon Stock	7,000	$8.21	$57,470.00	Disclosure SEC source: 0001415889-25-008920 · form4-03252025_090358.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,615 F1 · price: The weighted average purchase price for the transaction report was $8.21, and the range of prices were between $8.16 and $8.42, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document
August 16, 2024 Filed Aug 20, 2024 01:07 UTC	Immunome Inc. IMNM · Entity 4219	PurchaseCommon Stock	7,000	$13.94	$97,608.00	Disclosure SEC source: 0001415889-24-021659 · form4-08202024_010811.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,615 F1 · price: The weighted average purchase price for the transaction report was $13.944, and the range of prices were between $13.750 and $14.210. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document
June 13, 2024 Filed Jun 19, 2024 00:52 UTC	Immunome Inc. IMNM · Entity 4219	GrantStock option (right to buy) · Derivative	11,333	$0.00 Strike: $16.04	$0.00	Disclosure SEC source: 0001415889-24-017518 · form4-06192024_120605.xml · derivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,333 Underlying: Common Stock · 11,333 shares Expires 2034-06-12 F1 · derivative.exercise_date: The options vest in 4 quarterly installments, commencing from June 13, 2024 until the one year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date. Read SEC document
June 12, 2024 Filed Jun 14, 2024 16:17 UTC	INCYTE CORP INCY · Entity 3182	GrantNon Qualfied Stock Option (right to buy) · Derivative	12,517	$0.00 Strike: $59.94	$0.00	Disclosure SEC source: 0000879169-24-000097 · wk-form4_1718381833.xml · derivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,517 Underlying: Common Stock · 12,517 shares Expires 2034-06-11 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document
June 12, 2024 Filed Jun 14, 2024 16:17 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	2,830	$0.00	$0.00	Disclosure SEC source: 0000879169-24-000097 · wk-form4_1718381833.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,323 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including this grant, this includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
June 03, 2024 Filed Jun 5, 2024 20:11 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	GrantStock Option (right to buy) · Derivative	17,600	$0.00 Strike: $48.67	$0.00	Disclosure SEC source: 0001415889-24-015552 · form4-06052024_080645.xml · derivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2034-06-02 F1 · derivative.exercise_date: One-twelfth (1/12th) of the shares subject to the option shall vest in equal quarterly installments commencing on September 3, 2024, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
May 21, 2024 Filed May 22, 2024 20:49 UTC	Immunome Inc. IMNM · Entity 4219	PurchaseCommon Stock	2,000	$13.57	$27,139.80	Disclosure SEC source: 0001415889-24-014107 · form4-05222024_080525.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,615 Read SEC document
May 20, 2024 Filed May 21, 2024 20:09 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Tax withholdingCommon Stock	1,202	$77.05	$92,614.10	Disclosure SEC source: 0001048477-24-000086 · wk-form4_1716322162.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 473,792 Read SEC document
May 10, 2024 Filed May 13, 2024 19:57 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative	20,000	$0.00 Strike: $63.10	$0.00	Disclosure SEC source: 0001048477-24-000079 · wk-form4_1715630235.xml · derivative · entry 9 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 20,000 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document
May 10, 2024 Filed May 13, 2024 19:57 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	SaleCommon Stock	20,000	$81.14	$1,622,800.00	Disclosure SEC source: 0001048477-24-000079 · wk-form4_1715630235.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 474,994 F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Read SEC document
May 10, 2024 Filed May 13, 2024 19:57 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionCommon Stock	20,000	$63.10	$1,262,000.00	Disclosure SEC source: 0001048477-24-000079 · wk-form4_1715630235.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 494,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Read SEC document
May 09, 2024 Filed May 13, 2024 19:57 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative	20,000	$0.00 Strike: $63.10	$0.00	Disclosure SEC source: 0001048477-24-000079 · wk-form4_1715630235.xml · derivative · entry 8 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,000 Underlying: Common Stock · 20,000 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.